DexCom Inc.
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationa...
Latest News
15 hours ago · seekingalpha.com
DexCom: Improving Patient Access Makes It A Long-Term BuyDXCM's recurring sensor model synergizes nicely with wider diabetes access thanks to Medicare. In fact, broader Medicare coverage could expand their overall addressable market, as long as DXCM is able to execute on that expanded opportunity. Also, DXCM now offers longer-wear sensors, and they intend to increase their manufacturing scale. So, those factors combined could improve margins as well.
3 days ago · zacks.com
DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins RiseDXCM shares rise as Q3 earnings and revenues beat estimates, margins expand and 2026 guidance improves, driven by strong U.S. demand and G7 15 Day adoption.
3 days ago · seekingalpha.com
DexCom, Inc. (DXCM) Q3 2026 Earnings Call TranscriptDexCom, Inc. (DXCM) Q3 2026 Earnings Call Transcript
3 days ago · marketbeat.com
What DexCom (DXCM) Said on Its Q3 Earnings CallDexCom NASDAQ: DXCM reported third-quarter 2026 revenue of $1.34 billion, up 11% from a year earlier on both a reported and organic basis, as U.S. growth, market-share gains and manufacturing improvements supported higher profitability.
3 days ago · zacks.com
DexCom (DXCM) Surpasses Q3 Earnings and Revenue EstimatesDexCom (DXCM) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.61 per share a year ago.
3 days ago · benzinga.com
DexCom Q3 2026 Earnings Call TranscriptDexCom (NASDAQ:DXCM) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.
3 days ago · investors.com
Diabetes Wearable-Maker Handily Beats Earnings Views, Hikes Sales GuideDiabetes wearables-maker Dexcom topped third-quarter earnings forecasts Thursday and reported in-line sales. Dexcom stock was little moved.
3 days ago · businesswire.com
Dexcom Reports Third Quarter 2026 Financial ResultsSAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Third Quarter 2026 Financial Results.
5 days ago · businesswire.com
Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in NovemberBURNABY, British Columbia--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in Canada beginning next month for adults 18 years and older living with diabetes. Offering up to 15.5 days of wear,2 Dexcom G7 15 Day combines industry leading sensor duration with best-in-class accuracy,1 giving Canadians living with diabetes more time between sensor changes and.
5 days ago · prnewswire.com
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove DXCM